Iorga RA, Bacalbasa N, Carsote M, Bratu OG, Stanescu AMA, Bungau S, Pantis C, Diaconu CC (2020) Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review)
Ippei Ikushimas institution has also received funding to conduct clinical trials from Novo Nordisk, Eli Lilly and Company, Teijin Pharma, Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Sanofi K.K., Nippon Boehringer Ingelheim Co., and AstraZeneca
However, the review stresses that direct attribution of these effects to GLP-1R-mediated anti-inflammatory pathways remains to be conclusively demonstrated
The key to unlocking DSIPs restorative potential, including its role in physical recovery, is consistency, high-quality product/formulation, and proper dosing rather than chasing higher numbers
Research shows MK 677 can significantly increase growth hormone levels which in turn affects IGF-1 production, a key factor being studied in muscle growth and tissue regeneration in research models